$40 Million Series C Financing of Protagonist Therapeutics, Inc.

Represented Canaan Partners as a lead investor in successfully closing a $40 million Series C financing for Protagonist Therapeutics, Inc., a biotechnology company. The investment will fund continued advancement of the company’s oral peptide drugs for inflammatory bowel disease and other gastrointestinal diseases and disorders into clinical development.